PharmaTher and Vitruvias partner to commercialise Ketarx in US
Pharmaceutical Technology
JUNE 21, 2023
Ketarx will be marketed under the FDA-approved label of ketamine and in dosages that include 10mg/ml, 50mg/ml and 100mg/ml, with the option to boost the concentration and ready-to-administer applications. Ketamine is currently on the FDA’s drug shortage list. “We
Let's personalize your content